Startup Ships Mini Human Intestines by Mail, Because Mice Were Getting Too Much Credit for Our Digestion

America has finally found a use for the phrase "gut feeling" that does not involve a focus group. A Denver startup is growing tiny human intestines in a lab, packing roughly a hundred of them into a tube, and mailing them to pharmaceutical companies that have spent decades wondering why the mouse did fine and the patient did not.

Intero Biosystems calls the product GastroScreen. Each organoid is about one millimetre across, small enough to fit in a sentence and large enough, the company hopes, to stop another billion-dollar pill from discovering human biology in Phase III. Co-founder and CEO Charlie Childs put the business model without poetry: "We're literally shipping mini living organs in the mail to people." Somewhere, a postal worker is scanning a tube of guts and deciding this still beats the unmarked powder from last Tuesday.

The company spun out of the University of Michigan and now employs seven people, fewer humans than organoids per shipment. It has under ten customers, more than four hundred thousand dollars in recent revenue, and a two-point-three-million-dollar pre-seed. In biotech, that is a starter apartment: small, expensive to feed, and somehow full of potential.

Co-founder and CTO Madeline Eiken explained the problem with the old model in a line that belongs on every clinical consent form. "Most drugs fail clinical trials, and I think it's pretty easy to appreciate that we are neither mice nor flat layers of cells," she told TechCrunch. Mice have been the unpaid interns of Western medicine for a century. They absorb the toxins, clear the pathways, and then watch the same molecule fail in a creature that also owns a mortgage. It was never a fair internship.

GastroScreen is built from induced pluripotent stem cells, adult cells reprogrammed into the lining, muscle, vessels, and nerves of a miniature gut. Customers can keep them healthy or induce disease-like conditions, which is the first time "induce disease" has sounded like a product feature. Intero is midway through a three-stage validation process with drugs already known to soothe or wreck the intestine. Stage three will compare the tiny guts with animal and human data. If the millimetre agrees with the patient more often than the mouse, the mouse may finally retire.

Regulators have been nudging this direction. The FDA has been talking up "new approach methodologies," the bureaucratic name for anything that is not a rodent with a clipboard, and issued draft guidance on validating non-animal methods for submissions. The guidance endorses no specific gut-in-a-tube, which is how agencies say "we are interested, please do not sue us yet."

Intero took the Disrupt stage in San Francisco this week, pitching living mail-order organs while the rest of the conference argued about chatbots that cannot digest anything. Childs wants hundreds of thousands of organoids per batch. Ambition, in this sector, is measured in guts per hour. The long game is personalized medicine and, eventually, an artificial intestine.

So the future of safer drugs may arrive in a tube, one millimetre at a time, while mice enjoy an unexpected career change. We are neither mice nor flat layers of cells. We are the species that invented both the failed pill and the postage stamp, and has finally decided to put the second one to better use.